2020
Choosing Anticonvulsant Medications to Manage Status Epilepticus
Wu K, Hirsch LJ, Babl FE, Josephson SA. Choosing Anticonvulsant Medications to Manage Status Epilepticus. New England Journal Of Medicine 2020, 382: 2569-2572. PMID: 32579819, DOI: 10.1056/nejmclde2004317.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnticonvulsantsDisease ManagementDrug Therapy, CombinationEpilepsy, GeneralizedFemaleHumansLevetiracetamMidazolamPhenytoinStatus EpilepticusValproic Acid
2019
How long would it take to try all the antiepileptic drugs available?
Montenegro MA, Novais A, Hirsch LJ. How long would it take to try all the antiepileptic drugs available? Epilepsy Research 2019, 154: 77-78. PMID: 31096069, DOI: 10.1016/j.eplepsyres.2019.04.012.Peer-Reviewed Original ResearchAnticonvulsantsClinical Trials as TopicDrug Resistant EpilepsyDrug Therapy, CombinationHumansModels, TheoreticalTime Factors
2018
Comparative efficacy of unique antiepileptic drug regimens in focal epilepsy: An exploratory study
Legge AW, Detyniecki K, Javed A, Hirsch LJ, Kato K, Buchsbaum R, Chen B, Choi H. Comparative efficacy of unique antiepileptic drug regimens in focal epilepsy: An exploratory study. Epilepsy Research 2018, 142: 73-80. PMID: 29571152, DOI: 10.1016/j.eplepsyres.2018.03.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnticonvulsantsDrug Therapy, CombinationEpilepsies, PartialFemaleHumansLongitudinal StudiesMaleMiddle AgedTreatment OutcomeConceptsFocal epilepsyLamotrigine monotherapyUnique regimensSeizure freedomAntiepileptic drug polytherapyContinuous seizure freedomUnique antiepileptic drugAED regimensAED treatmentDrug polytherapyPersistent seizuresPhenytoin monotherapyAntiepileptic drugsEpilepsy severityPatient comparisonSix-month periodMonotherapyRegimensSame patientComparative efficacyBetter outcomesPatientsPolytherapyBetter efficacyEpilepsy
2015
Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: An extended follow-up
Javed A, Cohen B, Detyniecki K, Hirsch LJ, Legge A, Chen B, Bazil C, Kato K, Buchsbaum R, Choi H. Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: An extended follow-up. Seizure 2015, 29: 34-40. PMID: 26076842, DOI: 10.1016/j.seizure.2015.03.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnticonvulsantsCognitionCohort StudiesDrug Therapy, CombinationEpilepsyFemaleFollow-Up StudiesHumansIntellectual DisabilityLogistic ModelsMaleMiddle AgedPrognosisConceptsCognitive side effectsAntiepileptic medicationsSide effectsMultiple logistic regression analysisMore antiepileptic medicationsLogistic regression analysisQuality of lifeIndependent predictorsRetrospective studyAntiepileptic drugsAdult outpatientsMedical recordsAdverse effectsIntellectual disabilityPolytherapyLevetiracetamGabapentinRegression analysisLamotrigineLower ratesPredictorsCarbamazepineMonotherapyMedicationsRelative frequency
2008
Efficacy of Clobazam as Add-on Therapy for Refractory Epilepsy
Montenegro MA, Arif H, Nahm EA, Resor SR, Hirsch LJ. Efficacy of Clobazam as Add-on Therapy for Refractory Epilepsy. Clinical Neuropharmacology 2008, 31: 333-338. PMID: 19050410, DOI: 10.1097/wnf.0b013e31815cd960.Peer-Reviewed Original ResearchConceptsRefractory epilepsyEpilepsy centersColumbia Comprehensive Epilepsy CenterAntiepileptic drug regimenEfficacy of clobazamIntroduction of clobazamUS epilepsy centersUse of clobazamMultiple seizure typesComprehensive Epilepsy CenterAntiepileptic drug trialsPopulation of patientsAddition of clobazamMeasures of efficacyBinary logistic regressionDrug regimenSeizure freedomSeizure typesKaplan-MeierUS CentersDrug trialsPatientsUS FoodClobazamDrug Administration
2007
Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability
Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, Resor SR, Bazil CW. Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability. Epilepsia 2007, 48: 1351-1359. PMID: 17573925, DOI: 10.1111/j.1528-1167.2007.01043.x.Peer-Reviewed Original ResearchConceptsTolerability of levetiracetamLEV clearanceOlder adultsYoung adultsAdverse effectsEnzyme-inducing antiepileptic drugsOlder groupSame serum levelsCommon adverse effectsSubgroup of patientsGroup of patientsSpecific adverse effectsBehavioral side effectsOne-year retentionLevetiracetam pharmacokineticsEffect of ageOlder patientsYounger patientsApparent clearanceSerum levelsAntiepileptic drugsLEV useAdult outpatientsLow doseLevetiracetam
2005
Effect of Antiepileptic Drug Comedication on Lamotrigine Clearance
Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ. Effect of Antiepileptic Drug Comedication on Lamotrigine Clearance. JAMA Neurology 2005, 62: 1432-1436. PMID: 16157751, DOI: 10.1001/archneur.62.9.1432.Peer-Reviewed Original ResearchConceptsLamotrigine clearanceLamotrigine serum concentrationsNewer AEDsSerum concentrationsColumbia Comprehensive Epilepsy CenterComprehensive Epilepsy CenterLamotrigine monotherapyAdjunctive therapyMedical chartsEpilepsy centersComedicationMonotherapyBody weightPhenytoinValproatePatientsML/hAEDsClearanceSignificant predictorsCarbamazepineOxcarbazepinePredictorsLamotrigineTherapy
2004
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy
Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR, Morrell MJ. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004, 63: 1022-1026. PMID: 15452293, DOI: 10.1212/01.wnl.0000138424.33979.0c.Peer-Reviewed Original ResearchMeSH KeywordsAnticonvulsantsDose-Response Relationship, DrugDrug EruptionsDrug InteractionsDrug Therapy, CombinationEpilepsyFemaleGastrointestinal DiseasesHeadacheHumansLamotrigineMaleMental DisordersNervous System DiseasesRetrospective StudiesSleep Initiation and Maintenance DisordersTriazinesValproic AcidConceptsLamotrigine serum concentrationsSpecific side effectsAntiepileptic drugsSide effectsSerum levelsLTG levelsSerum concentrationsColumbia Comprehensive Epilepsy CenterConcomitant antiepileptic drugsLTG serum levelsComprehensive Epilepsy CenterRates of toxicityDuration of useInitial target rangeAED regimensRefractory patientsToxic regimenConcurrent medicationsSeizure freedomAdditional efficacyClinical toxicityEpilepsy centersLTG concentrationsClinical trialsDose changes
2003
Treatment of status epilepticus: a survey of neurologists
Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. Journal Of The Neurological Sciences 2003, 211: 37-41. PMID: 12767495, DOI: 10.1016/s0022-510x(03)00036-4.Peer-Reviewed Original ResearchConceptsAntiepileptic drugsStatus epilepticusCurrent treatment preferencesElimination of seizuresFourth-line treatmentTreatment of RSESecond-line therapyConvulsive status epilepticusFirst-line therapyNew antiepileptic drugsTraditional treatment paradigmSurvey of neurologistsIntravenous lorazepamSE refractoryTitration goalsMulticenter trialTreatment paradigmTreatment preferencesCritical careValproic acidBurst suppressionAmerican AcademyEpilepticusEpilepsy SectionTherapy